公开(公告)号：US12264160B2

公开(公告)日：2025-04-01

申请号：US18327607

申请日：2023-06-01

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li ,  Qiang Zhang ,  Robert Davis ,  Lawrence P. Wennogle

IPC: A61K31/437 ,  A61K9/48 ,  A61K9/50 ,  A61K31/4985 ,  A61K47/34 ,  A61K47/38 ,  C07D471/14 ,  C07D471/16 ,  C07D471/22

Abstract: The invention relates to pharmaceutical compositions comprising compounds of Formula Q: wherein W is —N(CH3)—, and Y is —C(O)—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.

公开(公告)号：US09944648B2

公开(公告)日：2018-04-17

申请号：US15110613

申请日：2015-01-09

Applicant: Intra-Cellular Therapies, Inc.

Inventor： Qiang Zhang ,  Youyi Peng ,  Peng Li ,  J. David Beard ,  Lawrence P. Wennogle ,  John Tomesch

IPC: C07D487/04 ,  C07D235/30 ,  C07D277/82 ,  C07B59/00 ,  C07D401/12

CPC classification number: C07D487/04 ,  C07B59/002 ,  C07B2200/05 ,  C07D235/30 ,  C07D277/82 ,  C07D401/12

Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.

公开(公告)号：US09708294B2

公开(公告)日：2017-07-18

申请号：US14993048

申请日：2016-01-11

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li ,  Youyi Peng ,  John Tomesch ,  Lawrence P. Wennogle ,  Qiang Zhang

IPC: A61K31/445 ,  C07D401/12 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/506 ,  A61K33/24 ,  A61K45/06 ,  A61K31/41 ,  A61K31/415 ,  A61K31/7068

CPC classification number: C07D401/12 ,  A61K31/41 ,  A61K31/415 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.